secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acumen Pharmaceuticals, Inc. (ABOS)
CIK:        0001576885
Form:       8-K
Filed at:   2022-01-03T23:59:59+00:00
Accession:  0001193125-22-000603
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Acumen Pharmaceuticals amends executive employment agreements with new base salaries and severance terms
--------------------------------------------------------------------------------

- CEO O'Connell: $551,200 base salary; 55% bonus target; 12-month non-CIC severance, 18-month CIC severance.
- CFO Zuga: $415,300 base; 40% bonus target; 9-month non-CIC severance, 12-month CIC severance with 1.0x bonus lump sum.
- CMO Siemers ($342,000 base) and COO Barton ($299,040 base) receive same severance structure as CFO.
- CIC severance includes full acceleration of time-based equity awards in addition to cash severance and COBRA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522000603/0001193125-22-000603-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1576885/000119312522000603/d245848d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-000603

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer